Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ELX 02

Drug Profile

ELX 02

Alternative Names: ELX-02; NB-124; Synthetic aminoglycoside

Latest Information Update: 21 Aug 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Technion - Israel Institute of Technology
  • Developer Eloxx Pharmaceuticals
  • Class Aminoglycosides; Antifibrotics; Small molecules
  • Mechanism of Action Ribosomal protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis; Mucopolysaccharidosis I; Rett syndrome; Cystinosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cystic fibrosis; Cystinosis
  • No development reported Duchenne muscular dystrophy; Mucopolysaccharidosis I; Rett syndrome

Most Recent Events

  • 12 Aug 2020 Eloxx Pharmaceuticals reinitiates enrolment in a phase II trial in Cystic fibrosis in the US (NCT04135495)
  • 04 Aug 2020 ELX 02 receives Orphan Drug status for Cystic fibrosis in USA
  • 04 Aug 2020 Eloxx Pharmaceuticals reinitiated a enrolment in its phase II trial in Cystic fibrosis in Israel and Germany before August 2020 (NCT04126473)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top